Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Inks Non-RNAi Tech-Evaluation Deal with Merck Subsidiary

Premium

Arrowhead Research said this week that it has signed a deal under which an undisclosed Merck subsidiary will evaluate a novel therapeutic monoclonal antibody candidate developed through its human-derived peptide targeting and discovery program.

Merck will be responsible for the costs associated with the arrangement. Additional terms were not disclosed.

Arrowhead picked up the peptide technology through its April acquisition of Alvos Therapeutics (GSN 4/12/2012).

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.